Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Toripalimab in Peritoneal Metastatic Carcinoma
NCT05030246Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, toripalimab in gastrointestinal carcinoma, primary peritoneal carcinoma (PPC), sponsored by Peking University. Status: unknown.
02
Drugs
surufatinibtoripalimab
03
Conditions
gastrointestinal carcinomaprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05030246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030246.